NEW YORK (360Dx) – Spanish diagnostics firm Bioprognos announced yesterday that it has received CE marking for MBDAA for Lung Neoplasia Dx — an algorithm used in the diagnosis of lung cancer — clearing it for sale in the European Union.
Get the full story
This story is free
for registered users
Registering provides access to this and other free content.
Register now.Already have an account?
Login Now.